Zehra Berberoğlu

491 total citations
16 papers, 325 citations indexed

About

Zehra Berberoğlu is a scholar working on Endocrinology, Diabetes and Metabolism, Reproductive Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Zehra Berberoğlu has authored 16 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Reproductive Medicine and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Zehra Berberoğlu's work include Ovarian function and disorders (4 papers), Bone health and treatments (2 papers) and GDF15 and Related Biomarkers (2 papers). Zehra Berberoğlu is often cited by papers focused on Ovarian function and disorders (4 papers), Bone health and treatments (2 papers) and GDF15 and Related Biomarkers (2 papers). Zehra Berberoğlu collaborates with scholars based in Türkiye and United States. Zehra Berberoğlu's co-authors include Ayşe Canan Yazıcı, Nilgün Güvener Demirağ, Neslihan Başçıl Tütüncü, Alptekin Gürsoy, Nilüfer Bayraktar, Süheyla Görar, Yalçın Aral, Aynur Aktaş, Feridun Karakurt and Sema Uysal and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Clinical Endocrinology and Acta Diabetologica.

In The Last Decade

Zehra Berberoğlu

16 papers receiving 309 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zehra Berberoğlu Türkiye 9 118 97 75 64 63 16 325
Adnan Gökçel Türkiye 8 45 0.4× 183 1.9× 37 0.5× 18 0.3× 17 0.3× 14 322
Gülçı̇n Şahin Ersoy Türkiye 13 95 0.8× 31 0.3× 247 3.3× 16 0.3× 21 0.3× 22 510
Fabio Taponeco Italy 11 68 0.6× 83 0.9× 44 0.6× 70 1.1× 181 2.9× 16 356
Pierre Kleynen Belgium 11 38 0.3× 176 1.8× 43 0.6× 27 0.4× 11 0.2× 18 309
Judith S. Renes Netherlands 10 101 0.9× 83 0.9× 13 0.2× 18 0.3× 28 0.4× 18 292
Denise L. Cassidenti United States 9 70 0.6× 99 1.0× 274 3.7× 44 0.7× 25 0.4× 15 465
Young Tae Kim South Korea 8 48 0.4× 140 1.4× 87 1.2× 7 0.1× 13 0.2× 13 347
O. Young United Kingdom 9 67 0.6× 101 1.0× 49 0.7× 62 1.0× 126 2.0× 9 355
Vitomir Tasevski Australia 10 79 0.7× 99 1.0× 11 0.1× 24 0.4× 15 0.2× 15 442
Alice Albu Romania 12 44 0.4× 96 1.0× 152 2.0× 13 0.2× 6 0.1× 32 334

Countries citing papers authored by Zehra Berberoğlu

Since Specialization
Citations

This map shows the geographic impact of Zehra Berberoğlu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zehra Berberoğlu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zehra Berberoğlu more than expected).

Fields of papers citing papers by Zehra Berberoğlu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zehra Berberoğlu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zehra Berberoğlu. The network helps show where Zehra Berberoğlu may publish in the future.

Co-authorship network of co-authors of Zehra Berberoğlu

This figure shows the co-authorship network connecting the top 25 collaborators of Zehra Berberoğlu. A scholar is included among the top collaborators of Zehra Berberoğlu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zehra Berberoğlu. Zehra Berberoğlu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Berberoğlu, Zehra. (2019). Pathophysiology of Gestational Diabetes Mellitus. 97–106. 52 indexed citations
2.
Berberoğlu, Zehra. (2015). Insight into Bone Metabolism and Skeletal Mass in Polycystic Ovary Syndrome. 46–53. 3 indexed citations
3.
Berberoğlu, Zehra, et al.. (2015). Hemostatic changes in gestational diabetes mellitus. International Journal of Diabetes in Developing Countries. 35(S3). 502–506. 6 indexed citations
4.
Görar, Süheyla, Ayşe Çarlıoğlu, Havva Yazıcı, et al.. (2014). Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. Journal of Endocrinological Investigation. 37(8). 715–719. 40 indexed citations
5.
Berberoğlu, Zehra, et al.. (2014). Association of plasma GDF-9 or GDF-15 levels with bone parameters in polycystic ovary syndrome. Journal of Bone and Mineral Metabolism. 33(1). 101–108. 22 indexed citations
6.
Berberoğlu, Zehra, et al.. (2014). Plasma GDF-15 levels and their association with hormonal and metabolic status in women with polycystic ovary syndrome aged 25-35.. PubMed. 39(2). 89–97. 7 indexed citations
7.
Berberoğlu, Zehra, et al.. (2014). Higher levels of circulating chemerin in both lean and obese patients with polycystic ovary syndrome.. PubMed. 66(6). 535–42. 11 indexed citations
8.
Berberoğlu, Zehra, et al.. (2013). Increased Total Renin Levels but Not Angiotensin-Converting Enzyme Activity in Obese Patients with Polycystic Ovary Syndrome. Medical Principles and Practice. 22(5). 475–479. 19 indexed citations
9.
Aktaş, Aynur, et al.. (2013). Higher levels of circulating CXCL-9 and CXCL-11 in euthyroid women with autoimmune thyroiditis and recurrent spontaneous abortions. Gynecological Endocrinology. 30(2). 157–160. 8 indexed citations
10.
Berberoğlu, Zehra, Ayşe Canan Yazıcı, Nilüfer Bayraktar, & Nilgün Güvener Demirağ. (2011). Rosiglitazone decreases fasting plasma peptide YY3–36 in type 2 diabetic women: a possible role in weight gain?. Acta Diabetologica. 49(S1). 115–122. 2 indexed citations
11.
Berberoğlu, Zehra, Ayşe Canan Yazıcı, & Nilgün Güvener Demirağ. (2010). ORIGINAL ARTICLE: Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2‐year follow‐up study. Clinical Endocrinology. 73(3). 305–312. 33 indexed citations
12.
Berberoğlu, Zehra, Nilgün Güvener, Banu Cangöz, et al.. (2009). Effects of Achieving an LDL-Cholesterol Level of <70 mg/dL Compared With the Goal of <100 mg/dL Using Simvastatin or Atorvastatin on Cognitive Processes in High-Risk Diabetic Patients. The Endocrinologist. 19(6). 271–279. 1 indexed citations
13.
Berberoğlu, Zehra, Nilgün Güvener, Mehmet Aşık, Ayşe Canan Yazıcı, & Nilüfer Bayraktar. (2009). Effects of Achieving LDL-Cholesterol Levels <70 mg/dL With Simvastatin or Atorvastatin on Steroidogenesis in High-Risk Diabetic Patients. The Endocrinologist. 19(3). 102–107. 1 indexed citations
14.
Ertuğrul, Derun Taner, Alptekin Gürsoy, Mustafa Şahi̇n, et al.. (2008). Evaluation of Brain Natriuretic Peptide Levels in Hyperthyroidism and Hypothyroidism. Journal of the National Medical Association. 100(4). 401–405. 26 indexed citations
15.
Berberoğlu, Zehra, Alptekin Gürsoy, Nilüfer Bayraktar, et al.. (2007). Rosiglitazone Decreases Serum Bone-Specific Alkaline Phosphatase Activity in Postmenopausal Diabetic Women. The Journal of Clinical Endocrinology & Metabolism. 92(9). 3523–3530. 92 indexed citations
16.
Ertuğrul, Derun Taner, Mustafa Şahi̇n, Aslı Doğruk Ünal, et al.. (2006). Effects of raloxifene on platelet functions in patients with postmenopausal osteoporosis. Platelets. 17(6). 351–353. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026